Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 3
2008 2
2009 3
2010 2
2011 3
2013 8
2014 6
2015 7
2016 8
2017 3
2018 4
2019 8
2020 3
2021 15
2022 9
2023 12
2024 20
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
The safety of JAK-1 inhibitors.
Clarke B, Yates M, Adas M, Bechman K, Galloway J. Clarke B, et al. Among authors: adas m. Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii24-ii30. doi: 10.1093/rheumatology/keaa895. Rheumatology (Oxford). 2021. PMID: 33950230 Free PMC article. Review.
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: adas ma. Ann Rheum Dis. 2023 Aug;82(8):1059-1067. doi: 10.1136/ard-2023-224049. Epub 2023 May 29. Ann Rheum Dis. 2023. PMID: 37247942 Free PMC article.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group. Garvey WT, et al. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. N Engl J Med. 2025. PMID: 40544433 Clinical Trial.
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. Deanfield J, et al. Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. Lancet. 2024. PMID: 39181597 Free article. Clinical Trial.
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Yates M, et al. Among authors: adas m. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. Arthritis Rheumatol. 2021. PMID: 33174384
The infection risks of JAK inhibition.
Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. Adas MA, et al. Expert Rev Clin Immunol. 2022 Mar;18(3):253-261. doi: 10.1080/1744666X.2022.2014323. Epub 2021 Dec 29. Expert Rev Clin Immunol. 2022. PMID: 34860621 Free PMC article.
128 results